

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

U.S. PATENT DOCUMENTS

| Examiner | Cite No. ¹ | Document Number Number Kind Code ³ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------|-----------------------|---|--------------------------------|--|---|
| CD | 340 | 2002/0162129 A1 | 10-31-2002 | Lannfelt | _____ |
| | 326 | 2002/0136718 A1 | 09-26-2002 | Raso | _____ |
| | 325 | 2001/0102261 A1 | 08-01-2002 | Raso | _____ / |
| | 306 | 6,417,178 B1 | 07-09-2002 | Klunk et al. | _____ / |
| | 342 | 2002/0009445 A1 | 01-24-2002 | Du et al. | _____ / |
| | 267 | 6,294,171 B2 | 09-25-2001 | McMichael | _____ |
| | 234 | 6,284,221 B1 | 09-04-2001 | Schenk, et al. | _____ |
| | 300 | 2001/0018053 A1 | 08-30-2001 | McMichael | _____ |
| | 230 | 6,262,335 B1 | 07-17-2001 | Hsiao et al. | _____ |
| | 345 | 2002/0077288 A1 | 06-21-2001 | Frangione | _____ |
| | 196 | 6,150,091 | 11-21-2000 | Pandolfo et al. | _____ |
| | 231 | 6,114,133 | 09-05-2000 | Seubert et al. | _____ |
| | 1 | 6,057,367 | 05-02-2000 | Stamler et al. | _____ |
| | 221 | 5,989,566 | 11-23-1999 | Cobb et al. | _____ |
| | 2 | 5,958,883 | 09-26-1999 | Snow | _____ |
| | 3 | 5,955,317 | 09-21-1999 | Suzuki et al. | _____ |
| | 4 | 5,955,079 | 09-21-1999 | Mond et al. | _____ |
| | 346 | 5,935,927 | 08-10-1999 | Vitek et al. | _____ |
| | 5 | 5,877,399 | 03-02-1999 | Hsiao et al. | _____ |
| | 6 | 5,869,093 | 02-09-1999 | Weiner et al. | _____ |
| | 7 | 5,869,054 | 02-09-1999 | Weiner et al. | _____ |
| | 8 | 5,854,204 | 12-29-1998 | Findeis et al. | _____ |
| | 9 | 5,851,996 | 12-22-1998 | Kline | _____ |
| | 10 | 5,849,298 | 12-15-1998 | Weiner et al. | _____ |
| | 321 | 5,837,672 | 11-17-1998 | Schenk et al. | _____ |
| | 11 | 5,837,473 | 11-17-1998 | Maggio et al. | _____ |
| | 353 | 5,824,322 | 10-20-1998 | Balasubramanian | _____ |
| | 12 | 5,786,180 | 07-28-1998 | Konig et al. | _____ |
| | 207 | 5,780,587 | 07-14-1998 | Potter | _____ |
| | 357 | 5,776,468 B1 | 07-07-1998 | Hauser et al. | _____ |
| | 13 | 5,753,624 | 05-19-1998 | McMichael et al. | _____ |
| | 14 | 5,750,349 | 05-12-1998 | Suzuki et al. | _____ |
| | 197 | 5,744,368 | 04-28-1998 | Goldgaber et al. | _____ |

Examiner Signature

Date Considered

7/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
PA 3307328 v1

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art. Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | | | |
|-----|--------------|------------|---------------------|--|
| 211 | 5,736,142 | 04-07-1998 | Sette et al. | |
| 15 | 5,733,547 | 03-31-1998 | Weiner et al. | |
| 16 | 5,688,651 | 11-18-1997 | Solomon | |
| 17 | 5,679,348 | 10-21-1997 | Neuburn et al. | |
| 18 | 5,645,820 | 07-08-1997 | Hafler et al. | |
| 19 | 5,641,474 | 06-24-1997 | Hafler et al. | |
| 20 | 5,641,473 | 06-24-1997 | Hafler et al. | |
| 356 | 5,622,701 | 04-22-1997 | Berg | |
| 21 | 5,612,486 | 03-18-1997 | McConlogue et al. | |
| 22 | 5,605,811 | 02-25-1997 | Saubert et al. | |
| 320 | 5,593,846 | 01-14-1997 | Schenk et al. | |
| 23 | 5,585,100 | 12-17-1996 | Mond et al. | |
| 358 | 5,583,112 B2 | 12-10-1996 | Kensil et al. | |
| 24 | 5,571,500 | 11-05-1996 | Hafler et al. | |
| 25 | 5,571,499 | 11-05-1996 | Hafler et al. | |
| 175 | 5,441,870 | 08-15-1995 | Seubert, et al. | |
| 26 | 5,434,170 | 07-18-1995 | Andruis, Jr. | |
| 27 | 5,387,742 | 02-07-1995 | Cordell | |
| 181 | 5,270,165 | 12-14-1993 | Van Nostrand et al. | |
| 284 | 5,231,170 | 07-27-1993 | Averback | |
| 28 | 5,231,000 | 07-27-1993 | Majocha et al. | |
| 29 | 5,220,013 | 06-15-1993 | Ponte et al. | |
| 30 | 5,208,036 | 05-04-1993 | Eppstein et al. | |
| 31 | 5,192,753 | 03-09-1993 | McGeer et al. | |
| 32 | 5,187,153 | 02-16-1993 | Cordell et al. | |
| 33 | 5,057,540 | 10-15-1991 | Kensil et al. | |
| 198 | 5,004,697 | 04-20-1991 | Pardridge | |
| 34 | 4,686,829 | 05-19-1987 | Glenner et al. | |

U.S. PATENT DOCUMENTS

| Examiner | Document Number | Filing Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|----------|-----------------|---------------------------|--|---|
| CGN | 60/254,405 | 12-08-2000 | Holzman et al. | |
| CGN | 60/254,496 | 12-08-2000 | Holzman et al. | |
| CGN | 60/474,843 | 11-20-2000 | Challfour et al. | |
| CGN | 60/184,601 | 02-24-2000 | Holzman et al. | |

Examiner Signature

G. Nichols

Date Considered

7/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 PA 3307328 v1

CONSIDERED; DO NOT PRINT.

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|---------------------|
| Substitute for form 1449A/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 09/724,567 |
| (use as many sheets as necessary) | | | | Filing Date | November 28, 2000 |
| Sheet | 3 | of | 21 | First Named Inventor | Dale B. Schenk |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | Christopher Nichols |
| | | | | Attorney Docket Number | 015270-005911US |

| | | | | |
|-----------|-----|------------|------------|------------------|
| <i>CN</i> | 282 | 00/109,667 | 12-08-1999 | Chain |
| ↓ | 342 | 00/169,594 | 11-29-1999 | Chalifour et al. |
| ↓ | 265 | 00/441,180 | 11-10-1999 | Solomon et al. |
| <i>CN</i> | 280 | 00/160,299 | 03-01-2000 | Rasmussen et al. |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---------------------------|---------------------|-----------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ² | Number ³ | Kind Code ⁴ (if known) | | |
| <i>CN</i> | 343 | EP | 1 172 378 | A1 | 01-16-2002 | |
| | 35 | EP | 911 036 | A2 | 04-28-1999 | |
| | 36 | EP | 866 918 | A2 | 10-07-1998 | |
| | 37 | EP | 863 211 | A1 | 09-09-1998 | |
| | 38 | EP | 845 270 | A1 | 06-03-1998 | |
| | 39 | EP | 782 859 | A1 | 07-09-1997 | |
| | 40 | EP | 683 234 | A1 | 11-22-1995 | |
| | 41 | EP | 666 080 | A1 | 08-09-1995 | |
| | 42 | EP | 652 962 | B1 | 12-16-1998 | |
| | 43 | EP | 639 081 | B1 | 11-03-1999 | |
| | 44 | EP | 613 007 | A2 | 08-31-1994 | |
| | 45 | EP | 594 607 | B1 | 08-27-1997 | |
| | 46 | EP | 561 087 | B1 | 08-04-1999 | |
| | 47 | EP | 526 511 | B1 | 05-28-1997 | |
| | 48 | EP | 506 785 | B1 | 03-15-2000 | |
| | 49 | EP | 451 700 | A1 | 10-16-1991 | |
| | 50 | EP | 440 619 | B1 | 01-24-1998 | |
| | 51 | EP | 359 783 | B1 | 11-29-1995 | |
| | 52 | EP | 276 723 | B1 | 12-08-1993 | Ver |
| | 187 | EP | 783 104 | A1 | 07-09-1997 | |
| | 351 | WO | 02/34878 | A2 | 05-02-2002 | |
| | 352 | WO | 02/34777 | A1 | 05-02-2002 | |
| | 341 | WO | 02/03911 | A2 | 04-07-2001 | |
| | 344 | WO | 01/90182 | A2 | 11-29-2001 | |
| | 345 | WO | 01/77167 | A2 | 10-18-2001 | |
| | 294 | WO | 01/62801 | A2 | 08-30-2001 | |
| | 301 | WO | 01/62284 | A2 | 03-01-2000 | |
| | 298 | WO | 01/42306 | A2 | 05-14-2001 | |

| | | | |
|--------------------|------------------|-----------------|---------|
| Examiner Signature | <i>G. Schenk</i> | Date Considered | 7/11/03 |
|--------------------|------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231 PA 3307328 v1

CONSIDERED DO NOT PRINT

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 21

| | |
|------------------------|---------------------|
| Application Number | 09/724,667 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | | | | | | |
|-----|----|----------|--------|------------|--|--|--|
| 243 | WO | 01/39796 | A2 | 06-07-2001 | | | |
| 199 | WO | 00/77178 | A1 | 12-21-2000 | | | |
| 322 | WO | 00/72880 | A2, A3 | 12-07-2000 | | | |
| 323 | WO | 00/72876 | A2, A3 | 12-07-2000 | | | |
| 324 | WO | 00/72870 | A1 | 12-07-2000 | | | |
| 240 | WO | 00/43039 | A1 | 07-27-2000 | | | |
| 188 | WO | 00/43049 | A1 | 07-27-2000 | | | |
| 53 | WO | 99/60024 | A1 | 11-25-1999 | | | |
| 54 | WO | 99/60021 | A2 | 11-15-1999 | | | |
| 55 | WO | 99/58564 | A1 | 11-18-1999 | | | |
| 56 | WO | 99/08066 | A2 | 02-11-1999 | | | |
| 57 | WO | 99/27949 | A1 | 06-10-1999 | | | |
| 58 | WO | 99/27944 | A1 | 06-10-1999 | | | |
| 59 | WO | 99/27911 | A1 | 06-10-1999 | | | |
| 331 | WO | 99/06545 | A2 | 11-02-1999 | | | |
| 203 | WO | 99/00150 | A2 | 01-07-1999 | | | |
| 60 | WO | 98/44955 | A1 | 10-15-1998 | | | |
| 61 | WO | 98/07850 | A2 | 02-26-1998 | | | |
| 202 | WO | 97/21728 | A1 | 06-19-1997 | | | |
| 62 | WO | 97/17613 | A1 | 05-15-1997 | | | |
| 63 | WO | 96/39176 | A1 | 12-12-1996 | | | |
| 208 | WO | 96/28471 | A1 | 09-19-1996 | | | |
| 64 | WO | 96/25435 | A1 | 08-22-1996 | | | |
| 65 | WO | 96/18900 | A1 | 08-20-1996 | | | |
| 66 | WO | 95/31986 | A1 | 11-30-1995 | | | |
| 200 | WO | 95/12815 | A1 | 05-11-1995 | | | |
| 67 | WO | 95/11994 | A1 | 05-04-1995 | | | |
| 68 | WO | 95/11311 | A1 | 04-27-1995 | | | |
| 227 | WO | 95/11008 | A2 | 04-27-1995 | | | |
| 69 | WO | 95/05853 | A1 | 03-02-1995 | | | |
| 70 | WO | 95/04151 | A2 | 02-09-1995 | | | |
| 201 | WO | 94/28412 | A1 | 12-08-1994 | | | |
| 71 | WO | 94/03615 | A1 | 02-17-1994 | | | |
| 72 | WO | 94/01772 | A1 | 01-20-1994 | | | |
| 73 | WO | 93/21950 | A1 | 11-11-1993 | | | |
| 74 | WO | 93/16724 | A1 | 09-02-1993 | | | |
| 75 | WO | 93/15760 | A1 | 08-19-1993 | | | |

Examiner Signature

G. Nichols

Date Considered

7/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3307328 v1

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | | | | | | |
|-----|----|-----------|----|------------|--|--|--|
| 76 | WO | 93/14200 | A1 | 07-22-1993 | | | |
| 205 | WO | 93/04194 | A1 | 03-04-1993 | | | |
| 77 | WO | 93/02189 | A1 | 02-04-1993 | | | |
| 78 | WO | 92/13069 | A1 | 08-06-1992 | | | |
| 79 | WO | 92/08708 | A1 | 04-30-1992 | | | |
| 80 | WO | 92/08187 | A1 | 04-16-1992 | | | |
| 81 | WO | 91/19810 | A1 | 12-26-1991 | | | |
| 82 | WO | 91/16819 | A1 | 11-14-1991 | | | |
| 83 | WO | 91/12816 | A1 | 09-05-1991 | | | |
| 84 | WO | 91/08760 | A1 | 06-27-1991 | | | |
| 85 | WO | 90/12871 | A1 | 11-01-1990 | | | |
| 86 | WO | 90/12870 | A1 | 11-01-1990 | | | |
| 87 | WO | 89/01343 | A1 | 02-23-1989 | | | |
| 88 | WO | 89/06242 | A1 | 07-13-1989 | | | |
| 89 | WO | 89/06689 | A1 | 07-27-1989 | | | |
| 90 | WO | 89/03687 | A1 | 05-05-1989 | | | |
| 91 | WO | 88/10120 | A1 | 12-29-1988 | | | |
| 92 | GB | 2 220 211 | A | 01-04-1990 | | | |
| 93 | GB | 2 335 192 | A | 09-15-1999 | | | |

| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>G. Nichols</i> | Date Considered | 7/11/03 |
|--------------------|-------------------|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
PA 3307328 v1

→

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0091
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,587 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|--------------------------|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| GSW | 94 | ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <i>Neurology</i> , 45:1441-1445 (1995). | <input type="checkbox"/> |
| | 95 | Associated Press, "Immune cells may promote Alzheimer's, a study finds," <i>The Boston Globe</i> (4/13/95). | <input type="checkbox"/> |
| | 176 | BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , 6(8):916-919 (2000). | <input type="checkbox"/> |
| | 228 | BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <i>J. Mol. Biol.</i> , 225(4): 1075-1093 (1992). | <input type="checkbox"/> |
| | 96 | BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Letters</i> , 285(1):111-114 (1991). | <input type="checkbox"/> |
| | 239 | BEASLEY, "Alzheimer's traced to proteins caused by aging," <i>Reuters</i> , April 20, 2001 7:56 PM ET. | <input type="checkbox"/> |
| | 204 | BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <i>Eur. J. Immunol.</i> , 29:345-354 (1999). | <input type="checkbox"/> |
| | 212 | BICKEL et al., "Site Protected, Galtonized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <i>Soc. for Neuroscience Abstracts</i> 18:784 (1992). | <input type="checkbox"/> |
| | 97 | BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <i>New England J. Medicine</i> , 341(22):1694 (1999). | <input type="checkbox"/> |
| | 98 | BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <i>Biochem. Biophys. Res. Comm.</i> , 171(2):890-897 (1990). | <input type="checkbox"/> |
| GSW | 99 | BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <i>Neuron</i> , 19: 939-945 (1997). | <input type="checkbox"/> |
| GSW | 100 | BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <i>Cur. Opin. Genet Develop.</i> , 3: 102-109 (1993). | <input type="checkbox"/> |

| | | | |
|--------------------|------------------|-----------------|---------|
| Examiner Signature | <i>G. Schenk</i> | Date Considered | 7/11/03 |
|--------------------|------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307328 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

7

of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | | |
|------------|-----|---|--------------------------|
| <i>CJG</i> | 101 | BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <i>J. Neurology, Neurosurg, Psychiatry</i> , 56:112-115 (1993). | <input type="checkbox"/> |
| | 327 | CAMERON, "Recent Advances In Transgenic Technology," <i>Molecular Biotechnology</i> , 7:253-265 (1997). | <input type="checkbox"/> |
| | 285 | CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <i>Clin. Neuropharm.</i> , 15:414A-414B (1992). | <input type="checkbox"/> |
| | 224 | Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm ; last updated May 16, 2002. | <input type="checkbox"/> |
| | 102 | CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <i>Soc. Neurosci. Abstracts</i> , 19:513-7 (1993). | <input type="checkbox"/> |
| | 266 | CHAPMAN, PAUL F., "Model behavior," <i>Nature</i> , 408:915-916 (2000). | <input type="checkbox"/> |
| | 222 | Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.) | <input type="checkbox"/> |
| | 332 | CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice," <i>Progress in Brain Research</i> . Van Leeuwen et al. Eds, 117:327-337 (1998). | <input type="checkbox"/> |
| | 307 | CHEN et al., A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. <i>Nature</i> . 408(6815):975-9 (2000). | <input type="checkbox"/> |
| | 213 | CHEN et al., "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <i>Neuroscience Letters</i> 125:223-226 (1991). | <input type="checkbox"/> |
| | 302 | CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β -Peptide by Microglial Cells," <i>J. Biol. Chem.</i> , 274(45):32301-32308 (1999). | <input type="checkbox"/> |
| <i>CDJ</i> | 291 | COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <i>Pharm. Res.</i> , 17:266-274 (2000). | <input type="checkbox"/> |
| <i>CDJ</i> | 333 | CONWAY et al., "Acceleration of oligomerization, not fibrilization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <i>PNAS</i> , 97(2):571-576 (2000). | <input type="checkbox"/> |

CONSIDERED DO NOT PRINT

| | | | |
|--------------------|----------------|-----------------|---------|
| Examiner Signature | <i>Giles Q</i> | Date Considered | 7/11/03 |
|--------------------|----------------|-----------------|---------|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307328 v1

→

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|---|---|----|----|--------------------------|---------------------|
| Substitute for form 1449B/PTO | | | | <i>Complete if Known</i> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/724,587 |
| Sheet | 8 | of | 21 | Filing Date | November 28, 2000 |
| | | | | First Named Inventor | Dale B. Schenk |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | Christopher Nichols |
| | | | | Attorney Docket Number | 015270-005911US |

| | | |
|-----|--|---|
| 286 | CORDELL, B., "β-Amyloid formation as a potential therapeutic target for Alzheimer's disease," <i>Ann. Rev. Pharmacol. Toxicol.</i> , 34:89-99 (1994). | — |
| 287 | COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <i>Scand. J. Immunol.</i> , 38:177-182 (1993). | — |
| 293 | DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <i>Life Sci.</i> , 63:2121-2131 (1998). | — |
| 214 | DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden In a Mouse Model of Alzheimer's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 101073/pnas.151281398 (2001). | — |
| 220 | Dialog/Derwent; Abstract of WPI Acc No: 1997-054436/199706. Stable vaccine compositions. — comprise a-macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water-sol. organic solvent and saline or water, Derwent File 354; Derwent-WPI database. (Publication date unknown.) | — |
| 318 | DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. <i>Neurology</i> , 57(5):801-5 (2001). | — |
| 103 | DUFF et al., "Mouse model made," <i>Nature</i> , 373: 476-477 (1995). | — |
| 288 | DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <i>Pathol. Biol.</i> , 49:72-85 (2001). | — |
| 225 | Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002). | — |
| 226 | Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002). | — |
| 104 | ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <i>J. Neurol. Sciences</i> , 59:341-347 (1983). | — |
| 289 | ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?" <i>Trends in Pharm. Sci.</i> , 22:2-3 (2001). | — |
| 105 | FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <i>Neuroscience Letters</i> , 152:185-189 (1993). | — |

CONSIDERED; DO NOT PRINT.

| | | | |
|--------------------|------------------|-----------------|---------|
| Examiner Signature | <i>G. Miller</i> | Date Considered | 7/11/03 |
|--------------------|------------------|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 330732& v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 9 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | |
|-----|---|---|
| 328 | FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing," <u>Alzheimer's and Parkinson's Disease</u> , Hainin et al. Ed., pp 401-409, Plenum Press, New York, (1995). | — |
| 106 | FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996). | — |
| 107 | FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991). | — |
| 108 | FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995). | — |
| 246 | FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001). | — |
| 247 | FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000). | — |
| 248 | FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1996). | — |
| 245 | FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <u>J. of Neuroimmunology</u> , 95:136-142 (1999). | — |
| 244 | FRENKEL, et al., "Modulation of Alzheimer's β -amyloid neurotoxicity by site-directed single chain antibody," <u>J. of Neuroimmunology</u> , 108:23-31 (2000). | — |
| 210 | FRIEDLAND et al., "Development of an anti- $A\beta$ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994). | — |
| 249 | FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997). | — |
| 109 | GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995). | — |
| 215 | GAMES et al., "Prevention and Reduction of AD-type Pathology In PDAPP Mice Immunized with $A\beta_{42}$," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000). | — |

Examiner Signature

Date Considered

7/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307328 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 10 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | |
|-----|---|
| 110 | GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992). |
| 251 | GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem. Biophys. Res. Comm.</u> , 173:1292-1298 (1990). |
| 111 | GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1188 (1993). |
| 252 | GEDDES, "N-terminus truncated beta-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999). |
| 253 | GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998). |
| 112 | GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998). |
| 114 | GLENNER et al., "Alzheimer's Disease and Down's Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984). |
| 113 | GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994). |
| 115 | GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991). |
| 303 | GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <u>Immunology</u> , 93:149-153 (1998). |
| 237 | GORTNER, <u>Outlines of Biochemistry</u> , pp. 322-323, John Wiley & Sons, Inc., New York (1949). |
| 116 | GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS USA</u> , 93:427-432 (1996). |
| 190 | GRAVINA et al., "Amyloid beta Protein (A β) In Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995). |
| 254 | GRUBECK-LOEBENSTEIN, et al., "Immunization with beta-amyloid: could T-cell activation have a harmful effect?", <u>TINS</u> , 23:114 (2000). |

| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>C. Nichols</i> | Date Considered | 7/11/03 |
|--------------------|-------------------|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307328 v1

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | |
|-----|---|
| 117 | GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <i>Vaccine</i> , 15(12/13): 1341-1343 (1997). |
| 241 | HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 359(6393):322-5 (1992). |
| 118 | HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <i>Brain Research</i> , 601:88-94 (1993). |
| 182 | HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <i>Int. J. Exp. Clin. Invest.</i> , 3:130-133 (1998). |
| 119 | HANES et al., "New advances in microsphere-based single-dose vaccines," <i>Advanced Drug Delivery Reviews</i> , 28: 97-119 (1997). |
| 120 | HARDY, "Amyloid, the presenilins and Alzheimer's disease," <i>TINS</i> , 20(4): 154-159 (1997). |
| 121 | HARDY, John, "New Insights Into the Genetics of Alzheimer's Disease," <i>Annals of Med.</i> , 28:255-258 (1996). |
| 255 | HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <i>Biochim. Biophys. Res. Comm.</i> , 211:1015-1022 (1995). |
| 193 | HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <i>Biochimica Biophysica Acta</i> , 1158:120-128 (1993). |
| 229 | HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2," <i>Immunology</i> , Vol. 78: 643-649 (1993). |
| 177 | HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <i>Science</i> , 289:375 (2000). |
| 236 | HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <i>Eur. J. Biochem.</i> , 201:61-69 (1991). |
| 122 | HSIAO et al., "Correlative Memory Deficits, β -Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> , 274: 99-102 (1996). |
| 123 | HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <i>J. Neuroimmunology</i> , 52:147-152 (1994). |

Examiner Signature

Date Considered

7/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3307328 v1

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. GMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 12 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

+
PRINT
DO NOT PRINT
CONSIDERED

| | |
|-----|--|
| 174 | Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown). |
| 124 | HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995). |
| 250 | IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987). |
| 125 | ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neurolmrtuology</u> , 24:173-182 (1989). |
| 192 | IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <u>Neuron</u> , 13:45-53 (1994). |
| 126 | JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982). |
| 308 | JANUS, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. <u>Nature</u> , 408(6815):979-82 (2000). |
| 257 | JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997). |
| 216 | JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> 138:373-384 (1991). |
| 334 | JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <u>Molecular Microbiology</u> , 5(7):1755-1767 (1991). |
| 347 | JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <u>Infection and Immunity</u> , May:497-502 (1981). |
| 127 | KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992). |
| 183 | KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996). |

| | | | |
|--------------------|-----------|-----------------|---------|
| Examiner Signature | G. Miller | Date Considered | 7/11/03 |
|--------------------|-----------|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3307328 v1

→

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

13

of 21

Complete if Known

| | |
|----------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |

Attorney Docket Number 015270-005911US

| | |
|-----|--|
| 128 | KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991). |
| 258 | KIDA, et al., "Early amyloid- β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of β -peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995). |
| 195 | KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the β A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996). |
| 129 | LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993). |
| 130 | LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990). |
| 131 | LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993). |
| 259 | LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Op. in Chemical Biology</u> , 1:260-267 (1997). |
| 132 | LEMERÉ et al., "Mucosal Administration of β -Peptide Decreases Cerebral Amyloid Burden In PD-APP Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999). |
| 260 | LEMERÉ, et al., "Nasal β -treatment induces anti- β -antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000). |
| 184 | LI and SOLOMON, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997). |
| 133 | LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997). |
| 134 | LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta Neurol. Scand.</u> , 84:441-444 (1991). |
| 218 | MAJOCZA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> , 33:2184-2189 (1992). |

| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>G. Nichols</i> | Date Considered | 7/11/03 |
|--------------------|-------------------|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307328 v1

→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|----|----|----|------------------------|---------------------|
| Substitute for form 1449B/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 09/724,567 |
| (use as many sheets as necessary) | | | | Filing Date | November 28, 2000 |
| Sheet | 14 | of | 21 | First Named Inventor | Dale B. Schenk |
| | | | | Art Unit | 1647 |
| | | | | Examiner Name | Christopher Nichols |
| | | | | Attorney Docket Number | 015270-005911US |

| | | | |
|-----------|-----|---|---|
| <i>SW</i> | 261 | MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <i>Brain Research</i> , 667:138-142 (1994). | — |
| | 263 | MANN, et al., "Amyloid β protein ($A\beta$) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $A\beta_{42(43)}$," <i>Annals of Neurology</i> , 40:149-156 (1996). | — |
| | 262 | MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <i>Neuroscience Letters</i> , 196:105-108 (1995). | — |
| | 335 | MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <i>PNAS</i> , 98(21):12245-12250 (2001). | — |
| | 217 | MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <i>Proc. Natl. Acad. Sci. USA</i> , 82:4245-4249 (1985). | — |
| | 309 | MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillrogenic derivatives. <i>Physiol Rev.</i> 77(4):1081-132 (1997). | — |
| | 135 | MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <i>J. Micro Encap.</i> , 14(2): 197-210 (1997). | — |
| | 264 | MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <i>J. of Neuroscience Res.</i> , 31:428-442 (1992). | — |
| | 238 | MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <i>Virology</i> , 243:158-166 (1998). | — |
| | 136 | MEDA et al., "Activation of microglial cells by β -amyloid protein and Interferon- γ ," <i>Nature</i> , 374:647-650 (1995). | — |
| | 265 | MENA, et al., "Monitoring pathological assembly of tau and β -amyloid proteins in Alzheimer's disease," <i>Acta Neuropathol.</i> , 89:50-56 (1995). | — |
| <i>CD</i> | 310 | MERLUZZI, et al. Humanized antibodies as potential drugs for therapeutic use. <i>Adv Clin Path.</i> 4(2):77-85 (2000). | — |
| <i>CD</i> | 137 | MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <i>J. Exp. Med.</i> , 174:791-798 (1991). | — |

| | | | |
|--------------------|------------------|-----------------|---------|
| Examiner Signature | <i>G. Miller</i> | Date Considered | 7/11/03 |
|--------------------|------------------|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3307328 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

15

of

21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | |
|------------|-----|---|
| <i>CJW</i> | 311 | MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-5 (2000). |
| | 206 | MORI et al., "Mass Spectrometry of Purified Amyloid β Protein In Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992). |
| | 233 | MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> , 39:1159-65 (1989). |
| | 359 | MUNCH et al., "Potential neurotoxic inflammatory response to A β vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087. |
| | 355 | MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York. |
| | 191 | MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994). |
| | 354 | MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany. |
| | 250 | NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995). |
| | 268 | NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (A β) subtypes (A β 40 and A β 42(43)) differentiates Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <u>Neuroscience Letters</u> , 201:151-154 (1995). |
| | 281 | NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998). |
| | 138 | NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997). |
| | 139 | New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94). |
| <i>CJW</i> | 235 | NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim. Biophys. Acta</u> , 104:480-486 (1965). |
| <i>CJW</i> | 329 | NIEMANN, "Transgenic farm animals get off the ground;" <u>Transgenic Research</u> 7:73-75 (1998). |

Examiner Signature

Schenk

Date Considered

7/11/03

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

' Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307328 v1

→

PTO/SB/08B (10-01)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|----|--------------------------|---------------------|
| Substitute for form 1449B/PTO | | <i>Complete If Known</i> | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Application Number | 09/724,567 |
| (use as many sheets as necessary) | | Filing Date | November 28, 2000 |
| Sheet | 16 | of | 21 |
| | | First Named Inventor | Dale B. Schenk |
| | | Art Unit | 1647 |
| | | Examiner Name | Christopher Nichols |
| | | Attorney Docket Number | 015270-005911US |

| | | |
|------------|-----|---|
| <i>CSA</i> | 280 | PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987). |
| | 140 | PARESCA et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996). |
| | 141 | PAUL et al., "Transdermal Immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995). |
| | 336 | PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002). |
| | 232 | PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996). |
| | 269 | PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996). |
| | 142 | PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994). |
| | 143 | QUON et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991). |
| | 145 | RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998). |
| | 144 | RASO, V.A., Grant application #1-R43-AGI 5746-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown). |
| | 144 | RASO, V.A., Grant application #1-R43-AGI 5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown). |
| | 146 | ROGERS et al., "Complement activation by β-amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992). |
| | 147 | ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 698:198-202 (1993). |
| <i>CSA</i> | 209 | RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," In <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1978). |
| <i>CSA</i> | 189 | SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993). |

| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>G. Nichols</i> | Date Considered | 7/11/03 |
|--------------------|-------------------|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3307328 v1

CONSIDERED, DO NOT PRINT

PTO/SB/05B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

17

of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | | |
|-----|-----|--|---|
| CSO | 194 | SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced In Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994). | — |
| | 279 | SAITO et al., "Vector-mediated delivery of ^{125}I -labeled β -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A β $^{1-40}$ vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995). | — |
| | 278 | SATOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti- β -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991). | — |
| | 277 | SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997). | — |
| | 148 | SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999). | — |
| | 312 | SCHENK, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. <u>DNA Cell Biol.</u> 20(11):679-81 (2001). | — |
| | 178 | SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995). | — |
| | 270 | SCHENK, et al., " β -peptide immunization," <u>Arch. Nuerol.</u> , 57:934-938 (2000). | — |
| | 150 | SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994). | — |
| | 151 | SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993). | — |
| | 149 | SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000). | — |
| | 155 | SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997). | — |
| | 152 | SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991). | — |
| CSO | 163 | SELKOE, Dennis J., "In the Beginning...," <u>Nature</u> , 354:432-433 (1991). | — |
| CSO | 313 | SELKOE, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. <u>Trends Cell Biol.</u> 8(11):447-53 (1998). | — |

Examiner
SignatureDate
Considered

7/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3307328 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 18 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | |
|-----|--|
| 154 | SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991). |
| 156 | SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992). |
| 157 | SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992). |
| 330 | SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000). |
| 314 | SIGURDSSON, et al. In vivo reversal of amyloid-beta lesions in rat brain. <u>J Neuropathol Exp Neurol</u> . 59(1):11-17 (2000). |
| 315 | SINHA, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. <u>Ann N Y Acad Sci</u> . 920:206-8 (2000). |
| 337 | SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech</u> , 18(1):34-39 (2000). |
| 319 | SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <u>Nat Rev Neurosci</u> . 2(8):595-8 (2001). |
| 158 | SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet Quart.</u> , 19(3): 101-105 (1997). |
| 185 | SOLOMON and GOLDSTEIN, "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996). |
| 166 | SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown). |
| 159 | SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS USA</u> , 94:4109-4112 (1997). |
| 160 | SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS USA</u> , 93:452-455 (1996). |
| 101 | SOLOMON, A., "Pro-Res (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown). |

CONSIDERED DO NOT POINT

| | | | |
|--------------------|----------------------|-----------------|---------|
| Examiner Signature | <i>C. M. Nichols</i> | Date Considered | 7/11/03 |
|--------------------|----------------------|-----------------|---------|

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307328 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 19 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

CONSIDERED DO NOT PRINT.

| | |
|-----|---|
| 162 | SOLOMON, B., "New Approach Towards Fast Induction of Anti- β -Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat Aviv, Tel-Aviv, Israel (publication date unknown). |
| 316 | SOTO, et al. Beta sheet breaker peptides Inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. <i>Nat Med.</i> 4(7):822-6 (1998). |
| 179 | SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease." <i>J. Neurochemistry</i> , 66:259-265 (1996). |
| 271 | ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, "Antibody clears senile plaques," <i>Nature</i> , 40:116-117 (1999). |
| 338 | STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways." <i>The Journal of Neuroscience</i> , 22(17):7380-7388 (September 1, 2002). |
| 163 | STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium falciparum Malaria</i> ," <i>N. Engl. J. Med.</i> , 336(2): 86-91 (1997). |
| 164 | STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <i>PNAS</i> , 94: 13287-13292 (1997). |
| 272 | SZENDREI, et al., "The effects of aspartic acid-bond Isomerization on in vitro properties of the amyloid β -peptide as modeled with N-terminal decapeptide fragments," <i>Int. J. Peptide Protein Res.</i> , 47:289-296 (1996). |
| 165 | TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <i>European J. Pharmacology</i> , 352:135-142 (1998). |
| 339 | TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <i>PNAS</i> , 92:4299-4303 (1995). |
| 273 | THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <i>Curr. Op. in Chem. Biology</i> , 4:377-382 (2000). |
| 276 | TJERNBERG et al., "Arrest of β -amyloid fibril formation by a pentapeptide ligand," <i>Journal of Biological Chemistry</i> , 271:8545-8548 (1996). |
| 166 | TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C.37, (1994). |

Examiner Signature

Christopher Nichols

Date Considered

7/11/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307328 v1

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 144B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

20

of

21

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | | |
|-------|----|----|----|
| Sheet | 20 | of | 21 |
|-------|----|----|----|

| | |
|-----|---|
| 167 | VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <i>Neuroscience Letters</i> , 172:122-124 (1994). |
| 317 | VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <i>DNA Cell Biol.</i> (11):713-21 (2001). |
| 168 | VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Amer. Journ. Pathology</i> , 144(1):104-116 (1994). |
| 169 | WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <i>J. Neuropath. Exp. Neurology</i> , 53(4):377-383 (1994). |
| 274 | WEINER et al., "Nasal administration of amyloid- β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <i>Annals of Neurology</i> , 48:567-579 (2000). |
| 171 | WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annu. Rev. Immunol.</i> , 12:809-837 (1994). |
| 172 | WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <i>Curr. Opin. Neurobiol.</i> , 7: 695-700 (1997). |
| 180 | WEN, G.Y., "Alzheimer's Disease and Risk Factors," <i>J. Food Drug Analysis</i> , 6(2):465-476 (1998). |
| 170 | WENGENACK et al., "Targeting Alzheimer amyloid plaques <i>In vivo</i> ," <i>Nature Biotech.</i> , 18:868-872 (2000). |
| 223 | WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologics", U.S. Govt. Res. Develop. Rep., 70(24), 38. (Publication date unknown.) |
| 219 | WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <i>PNAS USA</i> , 82:8729-8732 (1985). |
| 173 | WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS USA</i> , 94: 1550-1555 (1997). |
| 275 | WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier <i>In vivo</i> with a monoclonal antibody to the human insulin receptor," <i>J. Clin. Invest.</i> , 100:1804-1812 (1997). |

CONSIDERED; DO NOT PRINT.

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 7/11/03 |
|--------------------|---|-----------------|---------|

EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3307328 v1

→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 21 of 21

Complete If Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Dale B. Schenk |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| | | | |
|--------------------|-----|---|--------------------------|
| <i>[Signature]</i> | 292 | YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <i>Acta Neuropathol.</i> , 95:217-222 (1998). | <input type="checkbox"/> |
| <i>[Signature]</i> | 290 | YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," <i>Nature Medicine</i> , 7:18-19 (2001). | <input type="checkbox"/> |

| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>G. Nichols</i> | Date Considered | 7/11/03 |
|--------------------|-------------------|-----------------|---------|

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for PA 3307328 v1

PTO/SB/08B (04-03)

Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 09/724,567 |
| Filing Date | November 28, 2000 |
| First Named Inventor | Schenk, Dale B. |
| Art Unit | 1647 |
| Examiner Name | Christopher Nichols |
| Attorney Docket Number | 015270-005911US |

| NON PATENT LITERATURE DOCUMENTS | | |
|--|-----------------------|---|
| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| <i>CJN</i> | 349 | Check, "Battle of the Mind," <i>Nature</i> , 422:370-372 (March 2003). |
| <i>CJN</i> | 350 | Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report," <i>Nature Medicine</i> , 9(4):448-452 (April 2003). |

| | | | |
|--------------------|-------------------|-----------------|---------|
| Examiner Signature | <i>G. Nichols</i> | Date Considered | 7/11/03 |
|--------------------|-------------------|-----------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.86. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
PA 3305742 v1